Mar 13 |
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
|
Mar 10 |
Is Alnylam's HELIOS-B Delay A Red Flag?
|
Mar 6 |
Alnylam (ALNY), Roche's Blood Pressure Drug Meets Study Goal
|
Mar 5 |
Alnylam, Roche mark second Phase 2 win for blood pressure therapy
|
Mar 5 |
Roche, Alnylam say blood pressure drug succeeds in mid-stage trial
|
Mar 5 |
Alnylam, Roche blood pressure drug scores in second mid-stage trial
|
Mar 5 |
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
|
Feb 27 |
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
|
Feb 17 |
Alnylam Pharmaceuticals Full Year 2023 Earnings: In Line With Expectations
|
Feb 16 |
Alnylam (ALNY) Q4 Loss Narrower Than Expected, Stock Dips 10%
|